Exelixis, GSK Deal Comes To A ‘Natural, Positive End’
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK got what it came for, Exelixis’ CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Revised Alexza Deal Suggests Updated Strategy For Symphony Capital
With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006
Revised Alexza Deal Suggests Updated Strategy For Symphony Capital
With the dissolution of Symphony Allegro and the return of the joint venture's three clinical programs to Alexza, Symphony Capital should have its exit from the $50 million investment it made in the biotech and its Staccato aerosol inhalation technology in 2006
Exelixis Hopes To Avoid The Whole Capital Mess By Peddling Its Pipeline
Biotech outlines a post-GSK plan to operate without going to the capital markets while refocusing on internal development.